Citation Impact
Citing Papers
PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
2012
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
2013
Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
2015
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
2016
Development of siRNA Payloads to Target KRAS -Mutant Cancer
2014
Armed Antibodies Targeting the Mucin Repeats of the Ovarian Cancer Antigen, MUC16, Are Highly Efficacious in Animal Tumor Models
2007
Human Pancreatic Cancer Tumors Are Nutrient Poor and Tumor Cells Actively Scavenge Extracellular Protein
2015
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Oncogenic KRAS signalling in pancreatic cancer
2014
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
1998
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
2012
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Inflammatory networks and immune surveillance of pancreatic carcinoma
2013
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
2012 Standout
Genetically engineered mouse models of pancreatic adenocarcinoma
2013
Cancer Metastasis: Building a Framework
2006 Standout
Prodrug Strategies in Anticancer Chemotherapy
2007
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
2001
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
2003
Proliferation, cell cycle and apoptosis in cancer
2001 StandoutNature
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
3D superhydrophobic electrospun meshes as reinforcement materials for sustained local drug delivery against colorectal cancer cells
2012
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
The Clinical Utility of Biomarkers in the Management of Pancreatic Adenocarcinoma
2014
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
1997
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents
2000
Pancreatic Adenocarcinoma
2014 Standout
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 Standout
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Targeting apoptosis in cancer therapy
2020 Standout
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
1996
The microenvironment of the tumour–host interface
2001 StandoutNature
Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets
2002
Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer
2012
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
2016
Apoptosis
2002 Standout
Antisense therapy in oncology: new hope for an old idea?
2001
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
2013 StandoutNobel
Cancer immunotherapy comes of age
2011 StandoutNature
Understanding the Intersections between Metabolism and Cancer Biology
2017 Standout
Exploiting the bad eating habits of Ras-driven cancers
2013
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Prospects for MEK inhibitors for treating cancer
2014
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
2000 Standout
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
The PI3K Pathway in Human Disease
2017 Standout
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Arming antibodies: prospects and challenges for immunoconjugates
2005
Anemia of Chronic Disease
2005 Standout
A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
1999
Camptothecins: from bench research to hospital wards.
1994
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
2012
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Electrospinning and Electrospun Nanofibers: Methods, Materials, and Applications
2019 Standout
Bidirectional Photomodulation of Surface Tension in Langmuir Films
2016 StandoutNobel
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.
1995 StandoutNobel
Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice
2015
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
The Pancreas Cancer Microenvironment
2012
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
2003 Standout
The role of B7 family molecules in hematologic malignancy
2012
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
2012
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
2017
Metabolic reprogramming and cancer progression
2020 StandoutScience
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
2002 StandoutScience
HDACs and HDAC Inhibitors in Cancer Development and Therapy
2016
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
2008
Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas
2012
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
2015
Neoantigens in cancer immunotherapy
2015 StandoutScience
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
2005 Standout
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Multiple event activation of a generic prodrug trigger by antibody catalysis
1999 StandoutNobel
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Clinical Translation of Nanomedicine
2015
A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer
2006
Works of Lon Smith being referenced
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
2012
Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors
2014
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
1996
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
2013
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
2018
Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies
2000
Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.
2012
Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study
2003
Phase I and pharmacokinetic trial of weekly CPT-11.
1993
Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
2011
Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel
2001
Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors
1999